MOMasao Okadome

Masao Okadome

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masao Okadome has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characteristics and outcomes of women with adenocarcinoma versus squamous cell carcinoma of the vulva: A Japanese Gynecologic Oncology Group study

    by Shin Nishio, Koji Matsuo, Shinya Matsuzaki, Tomoyasu Kato, Shoji Kamiura, Hiroshi Adachi, Masao Okadome, Toshiaki Nakamura, Mikio Mikami, Takayuki Enomoto


  • Open Access

    Potential alternative progestin therapy for low-grade endometrial stromal sarcoma: A case report

    by Shoji Maenohara, Takahiro Fujimoto, Masao Okadome, Kenzo Sonoda, Kenichi Taguchi, Toshiaki Saito


  • Open Access

    Prognosis of bulky pTIIB cervical cancer treated by radical hysterectomy comparing adenocarcinoma with squamous cell carcinoma using propensity score matching

    by Masao Okadome, Rina Nagayama, Mototsugu Shimokawa, Kenzo Sonoda, Kumi Shimamoto, Toshiaki Saito

    Objective: To investigate whether radical hysterectomy (RAH) can effectively treat true Stage IIB (pTIIB) cervical adenocarcinoma (AC) because FIGO (clinical) Stage IIB cervical cancer is rarely treated with RAH and radiotherapy has unfavorable effects on AC. Methods: We retrospectively analyzed data for 82 patients with Stage pTIIB cervical cancer who underwent RAH at our institution between January 1997 and December 2017. The end points were disease‐free survival (DFS) and overall survival (OS) among squamous cell carcinoma (SCC) (n = 60) and AC (n = 22) patients. Kaplan–Meier survival analysis with and without propensity score matching was conducted to identify the impact of RAH. Results: Para‐aortic lymph node metastasis and tumor diameter were significant factors for recurrence, and adjuvant chemotherapy prevented recurrence on multivariate analysis. After propensity score matching, there was no significant difference in DFS and OS between the groups. Five‐year DFS and OS of the SCC group were 0.505 (95% confidence interval [CI] 0.268–0.702) and 0.619 (95% CI 0.351–0.803), respectively, and those of the AC group were 0.444 (95% CI 0.232–0.638) and 0.602 (95% CI 0.351–0.782), respectively. Conclusion: Bulky Stage pTIIB cervical cancer is hard to cure, but RAH plus adjuvant therapy might be an option for radio‐resistant pTIIB cervical AC.


  • Open Access

    Diagnostic benefit of cytological and histopathological examinations for recurrent vaginal cancer metastasizing to the duodenum: A case report

    by Kenzo Sonoda, Masao Okadome, Rie Sugimoto, Takahiro Fujimoto, Kenichi Taguchi, Toshiaki Saito

    This is the first case report of a vaginal squamous cell carcinoma that metastasized to the duodenum. Cytological and histopathological examinations are useful for the diagnosis of a duodenal metastasis.


  • A Glint of Hope for Treatment of Advanced Malignant Transformations of Ovarian Mature Cystic Teratomas: A Retrospective Analysis of 9 Cases

    by Yui Tomita, Toshiaki Saito, Masao Okadome, Kenzo Sonoda, Kazuya Ariyoshi, Kumi Shimamoto, Rina Nagayama, Shoko Kitade, Shoji Maenohara

    Objective: Malignant transformation of a mature cystic teratoma (MTMCT) of the ovary is extremely rare; the occurrence rate is ∼1%–3% of all mature cystic teratomas. Because of the rarity of MTMCT, there are many unknown aspects of its clinical findings, treatment, and prognosis. Prognosis for MTMCT is reportedly worse than that of epithelial ovarian cancer. A retrospective study was performed with 9 patients in the Gynecology Service, of the National Kyushu Cancer Center, in Fukuoka, Japan, to explore MTMCT's clinical findings and prognosis. Materials and Methods: This was a retrospective study of nine cases of MTMCT treated in the hospital from January 2000 to December 2017. Results: The median age of the 9 patients was 65. The median survival time was 20.5 months (range: 11–127 months). Among the patients, 5 (55.5%) were determined to have advanced stage III or IV MTMCT. All patients underwent hysterectomy with bilateral salpingo-oophorectomy and omentectomy. Five patients (55.5%) underwent more-extended debulking surgery, including intestinal-tract and ureter resection. All patients received postoperative adjuvant treatments. Unexpectedly, however, 3 of 5 patients with advanced disease (stage III/IV) survived for more than 5 years. None of the surviving patients developed recurrences after the initial treatment. Conclusions: MTMCT is a malignant disease with a poor prognosis even in the early stage. However, some patients with advanced MTMCT can have long-term survival even with poor prognostic factors, such as lymph-node metastases and intestinal invasions. The prognosis may be improved by performing maximal tumor reduction and appropriate adjuvant therapy. (J GYNECOL SURG 36:184)


  • Renal function and urological complications after radical hysterectomy with postoperative radiotherapy and platinum-based chemotherapy for cervical cancer

    by Masao Okadome, Toshiaki Saito, Shoko Kitade, Kazuya Ariyoshi, Kumi Shimamoto, Hiroyuki Kawano, Kazuhito Minami, Motonobu Nakamura, Mototsugu Shimokawa, Kazuhiro Okushima, et al.

    We aimed to clarify renal functional changes long term and serious urological complications in women with cervical cancer who undergo radical hysterectomy followed by pelvic radiotherapy and/or platinum-based chemotherapy to treat the initial disease. Data on 380 women who underwent radical hysterectomy at the National Kyushu Cancer Center from January 1997 to December 2013 were reviewed. Main outcome measures were the estimated glomerular filtration rate (eGFR) and monitored abnormal urological findings. Postoperative eGFR was significantly lower than preoperative eGFR in 179 women with surgery alone and in 201 women with additional pelvic radiotherapy and/or chemotherapy (both P < 0.01). Two types of univariate analyses for eGFR reduction in women after treatment showed that older age, advanced stage, pelvic radiotherapy, and platinum-based chemotherapy were significant variables on both analyses. Two types of multivariate analyses showed that platinum-based chemotherapy or pelvic radiotherapy were associated with impaired renal function (odds ratio 1.96, 95% confidence interval 1.08–3.54 and odds ratio 2.85, 95% confidence interval 1.12–7.24, for the respective analyses). There was a higher rate of bladder wall thickening in women with pelvic radiotherapy had than those without it (17.4% vs. 2.7%, P < 0.01). One serious urological complication (intraperitoneal rupture of the bladder) occurred among women who underwent pelvic radiotherapy (0.6% vs. 0%). Surgeons should be aware that eGFR is reduced after platinum-based chemotherapy and/or postoperative pelvic radiotherapy. Serious and life-threatening urological complications are rare, but surgeons should be aware of the possibility during the long follow-up.


    • 1 July 2015
      • Vol. 42  (7) , 821-5

    [Nogitecan Hydrochloride Treatment for Patients with Recurrent Ovarian Cancer].

    by Kumi Shimamoto, Toshiaki Saito, Rina Nagayama, Shinichiro Yamaguchi, Takako Shimada, Kazuya Ariyoshi, Masao Okadome

    Nogitecan hydrochloride(topotecan)has shown efficacy in patients with recurrent ovarian cancer, but has not been used widely in Japan. We evaluated the efficacy and adverse effects of topotecan in 12 patients (median age, 62 years) treated for recurrent ovarian cancer between 2000 and 2013. Four patients had relapsed after primary treatment, and 8 had relapsed at least twice. Seven patients had been treated with more than 3 prior regimens. Initial treatment of the 12 patients consisted of intravenous topotecan (1.0-1.4 mg/m2/day) for 5 consecutive days. Initial doses were based on previous chemotherapy and/ or renal function, with reduced doses administered to patients with severe adverse effects during prior courses of treatment. The 12 patients received a total of 54 courses of topotecan(range, 1-15 courses). Of these 12 patients, one achieved a partial response and 6 had stable disease. The median time to progression was 14.4 weeks. All 12 patients had grade 3-4 myelosuppression, while none had febrile neutropenia or severe non-hematologic toxicities. Patients who received higher doses or increased courses of chemotherapy had apparently more severe adverse events. These findings suggested that topotecan should be used as a second- or third-line treatment, rather than later, in patients with tumor recurrence, with its dose reduced according to the physical status of each patient. Such strategies may enhance both the efficacy and safety of topotecan in patients with recurrent ovarian cancer.

  • Immune thrombocytopenia associated with solid cancer

    by Takako Shimada, Toshiaki Saito, Ilseung Choi, Shinichiro Yamaguchi, Kumi Shimamoto, Kazuya Ariyoshi, Masao Okadome

    We describe a case of immune thrombocytopenia (ITP) associated with ovarian cancer. At the patient's first visit to hospital, high platelet-associated IgG and low platelet count (74 × 10(9)/L) were noted on blood test. She was diagnosed as having ITP complicated by ovarian cancer. Four days after surgery, the platelet count had increased to within the normal range. This is the first report of a patient with ITP complicated by ovarian cancer in which the platelet count reverted to normal soon after surgery for the ovarian cancer. We also investigated the characteristics of similar solid cancers with ITP at National Kyushu Cancer Center, Fukuoka, Japan.


  • Open Access

    Early Identification of Asymptomatic Pulmonary Embolism Proximal to the Subsegmental Arteries After Gynecologic Surgery

    by Masao Okadome, Toshiaki Saito, Kumi Shimamoto, Rihoko Ogahara, Hiromi Akiyoshi, Minoru Fujimoto, Kenji Shinozaki

    Few studies have assessed whether cases of asymptomatic pulmonary embolism (PE) in the early postoperative phase are subsegmental versus more proximal. In this study, we investigated whether asymptomatic PE occurring just after gynecologic surgery was subsegmental, and we examined the background characteristics of patients who experienced PE within 2 months postoperatively. All hospital records were reviewed, yielding a total of 2052 women who had undergone surgeries performed by the gynecologic oncology team between 2003 and 2013 in the National Kyushu Cancer Center. Asymptomatic and symptomatic postoperative PE cases diagnosed by multidetector computed tomography angiography or lung scan were identified; after excluding 2 cases of preoperative PE, there were 15 (0.73%) cases of postoperative PE among 2050 women. Of the 15 cases, 9 (60%) were diagnosed on postoperative day 1 or 2. Of the 9 women, 4 had no or minor symptoms/signs other than decreased oxygen saturation as measured by pulse oximetry (Spo2), and PE was segmental or more proximal in 3 cases. Only 1 of the 9 cases showed dyspnea. The remaining 4 cases showed dizziness or perspiration, suggesting PE. Univariate analysis showed age, operation time, hypertension, and preoperative d-dimer elevation to be associated with postoperative PE. Multivariate analysis demonstrated that a high (≥1 µg/mL) preoperative d-dimer level was associated with postoperative PE (odds ratio, 6.331; 95% confidence interval, 1.567-25.589). Most asymptomatic PE cases occurring within 2 days postoperatively were segmental or more proximal. Identification of early, asymptomatic postoperative PE may be clinically significant because most of these emboli are proximal to the subsegmental arteries.

  • Prediction of histological types of endometrial cancer by endometrial cytology

    by Masao Okadome, Toshiaki Saito, Naoko Nishiyama, Kazuya Ariyoshi, Kumi Shimamoto, Takako Shimada, Keisuke Kodama, Shogo Imamura, Ken-Ichi Nishiyama, Kenichi Taguchi

    Few studies have examined the accuracy of preoperative endometrial cytology in diagnosing low- and high-risk histology in women with endometrial cancer (EC). This single-institutional retrospective study compared the accuracy of endometrial cytology and biopsy in preoperatively predicting low-risk and high-risk histology of EC. Between January 2006 and March 2013, 198 women with EC were examined by endometrial cytology, endometrial biopsy and hysterectomy specimen in National Kyushu Cancer Center. Among these women, 110 had endometrial cytology samples available to compare with endometrial biopsy, and were enrolled in our study (mean age ± standard deviation: 59.57 ± 10.32 years). Single-use plastic endometrial suction curettes were used in 12 of the 110 cases and thin metallic curettes for the rest. For type 2 EC, which includes grade 3 endometrioid adenocarcinoma and non-endometrioid histology, biopsy was 67.6% sensitive (25/37) and 84.9% specific (62/73); whereas cytology was 70.3% sensitive (26/37) and 91.8% specific (67/73). Cytology precisely diagnosed only one of 14 cases of serous carcinoma, but it diagnosed 11 of the 14 cases as type 2 EC, and its accuracy in distinguishing EC types was not inferior to endometrial biopsy (10/14). For EC, 9.1% (10/110) were unevaluable using biopsy, significantly more than the 0% (0/110) by cytology (P = 0.002). Although preoperative prediction of serous carcinoma was difficult, endometrial cytology had a higher evaluable rate for EC types. Endometrial cytology may complement endometrial biopsy in preoperative women with EC.